November 20, 2013
QIAGEN Announces Third Co-Development Program for Companion Diagnostics Paired With Lilly’s Investigational Cancer Compounds – WSJ.com
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced an agreement with Eli Lilly and…
November 19, 2013
71st Edition – November 19, 2013
You're receiving this newsletter because of your interest in BioHealth Innovation Having trouble viewing this…
November 18, 2013
Maryland entrepreneurs share crowdfunding success stories – Baltimore Business Journal
For budding startups, accumulating funding is necessary — but difficult. Crowdfunding can be a viable…
November 18, 2013
No luck landing VC? Try ‘credit cards, duct tape and shoestrings’ – Baltimore Business Journal
Paul Silber had some unexpected advice from a venture capitalist for the entrepreneurs who crowded…
November 18, 2013
Why Can’t You Take Your Medical Data on Holiday?: Scientific American
We’ve all done it. You throw your clothes in a bag and head to the…
November 18, 2013
What’s driving the surge in new-drug approvals? | McKinsey & Company
Much has been written about the pharmaceutical industry’s R&D-productivity challenge during the past decade: the…
November 18, 2013
GlaxoSmithKline’s $15 million new asthma drug approved
GlaxoSmithKline and Theravance's new inhaled lung drug Relvar has been approved in Europe to treat…
November 18, 2013
QIAGEN announces third co-development program for companion diagnostics paired with Lilly’s investigational cancer compounds
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced an agreement with Eli Lilly and…
